Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
The present invention relates to compounds, and methods of use thereof, capable of entering macrophages. The invention further relates to compounds capable of modulating (for example inhibiting) the activity of the mammalian target of rapamycin (mTor), treating mTor-associated diseases, in particular, but not limited to, related to mTor in macrophages. The invention also relates to compounds capable of imaging mTor in a subject, in particular, but not limited to, mTor in macrophages.
1. A process for preparing a product, comprising the steps:
coupling a secondary alcohol at carbon position 43 of rapamycin with a bromo-substituted acyl chloride to obtain an intermediate A, wherein R is X-L-Br,
reacting intermediate A at room temperature in one portion to a solution of a sodium salt of a compound of Formula 1 in dimethylformamide:
wherein,
X is carbonyl or a bond;
Y and Z are each independently selected from the group consisting of bond, oxygen, carbonyl, and amine, and Y having a point of attachment to L;
L is a linker comprising at least one selected from the group consisting of a bond, an alkyl, a branched alkyl, an aryl, an ester, an ether, and an amide;
R 1 , R 2 , R 3 , R 4 , and R 5 are each independently selected from the group consisting of H, F, Cl, Br, I, NR 6 R 7 , NR 6 C(═O)R 7 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein R 6 and R 7 are selected from the group consisting of H, and optionally substituted C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl;
n is 1 or 2;
under reaction conditions effective to obtain a product of the formula
2. The process according to claim 1 , wherein the product is selected from the group consisting of:
3. The process according to claim 1 , wherein the product is represented by Formula 2:
4. The process according to claim 1 , further comprising the step of purifying the product by dissolving in ethyl acetate at room temperature, and then slowly adding ethyl acetate solution of the product into a solution of hexane dropwise and stirring at RT for 30 min, collecting a solid filter cake formed by vacuum filtration, and washing the filter cake with hexane.
5. The process according to claim 2 , further comprising the step of purifying the product by recrystallization in ethyl acetate/hexane.
6. The process according to claim 1 , wherein intermediate A is obtained by reacting a solution of rapamycin and pyridine in dry dichloromethane with a solution of 6-bromohexanoyl chloride in dry cold DCM under nitrogen under conditions effective to produce intermediate A.